FTH 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• We are a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. On February 17, 2026, we completed the Acquisition of Faeth Therapeutics, a clinical-stage biotechnology company developing multi-node therapi…

• Following the Acquisition, our lead program is PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in on…

• Prior to the Acquisition, we were primarily focused on the development of solnerstotug (formerly SNS-101), our conditionally active monoclonal antibody targeting the immune checkpoint VISTA. We are completing the remaining portion of the solnerstotug Phase 1/2 trial with patients currently on study.

• We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. Our net loss was $170.2 million and $6.9 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit …

• Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• We are a clinical-stage biotechnology company that has been focused on the discovery and development of next-generation therapeutics for cancer patients.

• On October 30, 2025, we announced the discontinuation of development of our lead product candidate, solnerstotug, and initiated a comprehensive review of strategic alternatives to maximize stockholder value. These alternatives include, but are not limited to, a sale of assets, licensing arrangements…

• On November 14, 2025, we announced the implementation of a workforce reduction to preserve cash, pursuant to which we reduced our workforce by approximately 65% (the “2025 Workforce Reduction”). We expect to incur aggregate cash charges of approximately $1.6 million in connection with the 2025 Workf…

• We are devoting substantial time and resources to the strategic review. Despite devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if …

• Our pipeline consists of one clinical-stage program and three preclinical programs.

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• On February 17, 2026, we completed our acquisition of Faeth Therapeutics, as further described in Note 3 to the condensed consolidated financial statements included elsewhere in this Quarterly Report. In connection with the acquisition, we have begun the process of integrating Faeth Therapeutics' fi…

• Other than as described above, there were no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2026 which have materially affected, or are reasonably likely to m…

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• There were no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended September 30, 2025 which have materially affected, or are reasonably likely to materially affect, our inter…

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• We have a limited operating history, have incurred net losses since our inception, and anticipate that we will incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.

• If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.

• We need substantial additional funding to complete the development of our product candidates. A failure to obtain this necessary capital when needed could force us to further delay, limit, reduce or terminate our product development or commercialization efforts.

• We were not involved in the early development of PIKTOR; therefore, we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical trials of PIKTOR.

• While emerging clinical data from a competitor has provided evidence supporting the multi-node inhibition concept, there is no guarantee that PIKTOR’s specific approach will produce comparable results, and a competitor’s first-mover advantage could limit our commercial opportunity.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• Our activities to evaluate and pursue potential strategic alternatives may not result in any transaction or enhance stockholder value.

• Our recently implemented corporate restructuring intended to optimize our resource allocation and contain costs may not have the benefits we expect.

• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.

• We would need additional funding to re-initiate and complete the development of our product candidates. A failure to obtain this necessary capital when needed could force us to further delay, limit, reduce or terminate our product development or commercialization efforts.

• We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• As part of the cash preservation associated with the strategic review process, our Board of Directors (the “Board”) has approved a reduction in force of approximately 65% of our workforce. The reduction in force is expected to be completed during the fourth quarter of 2025. We estimate that we will …

• Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

• On November 13, 2025, in connection with the reduction in force described above, our Board determined to terminate John Celebi, our Chief Executive Officer, Edward van der Horst, our Chief Scientific Officer, and Stephanie Krebs, our Chief Business Officer, effective as of 5:30 p.m. ET on November 1…

• In addition, each of Mr. Celebi, Dr. van der Horst and Ms. Krebs have entered into Consulting Agreements with the Company (collectively, the “Consulting Agreements”), effective as of November 14, 2025, pursuant to which they will perform consulting services for the Company. The Consultant Agreements…

• Appointment of Christopher W. Gerry as President and Principal Executive Officer